The Center for Precision Medicine aims to be the leader in improving the quality of patient care with targeted prevention, precise diagnosis, and personalized treatments.
Basic research teams in the Center are involved in making fundamental discoveries of the genetic causes of heart diseases, cancer, diabetes, pulmonary, and neurological disorders. Dr. Edward T.H. Yeh founded the Department of Cardiology at the University of Texas, MD Anderson Cancer Center in 2000. His laboratory made the critical discovery that Topoisomerase 2b is the molecular basis of anthracycline-induced cardiotoxicity. This discovery changed the 40-year-old-paradigm that anthracycline toxicity is due to ROS generation alone and provided new insight for prevention.
Dr. Yeh also made fundamental contributions in biochemistry by discovering two ubiquitin-like proteins (SUMO/Sentrin and NEDD8) that exemplify the importance of post-translational protein modification in biology and medicine. Using genetic animal models, he showed that SUMO and NEDD8 are important in the regulation of hypoxia-inducible factor stability, DNA repair, heart and lymphoid development, cancer pathogenesis, and sudden death and seizure disorders. These basic discoveries are being translated into clinical applications.
In addition to discovery research, the Center will also build platforms to integrate access to a large database, remote sensing devices, and electronic health records. These platforms will be staffed by bio-informaticians, bio-statisticians, and database programmers to conduct research on clinically relevant and patient-centered issues. Clinical interests of the Center include, but are not limited to: onco-cardiology, cystic fibrosis, congestive heart failure, stem cell therapies, degenerative diseases, and metabolic disorders.